Summary – In the world of drug discovery, for the most part, it hasn’t changed much in decades. Ross Youngs, CEO of Biosortia Pharmaceuticals, is looking to change that with a better understanding of the microbiome.

PODCAST: 9/24/2020

(September 24, 2020) | By Ammon Rivera.

Through an interesting turn of events, Biosortia discovered they had access to large amounts of Aquatic Microbiome. With a broad range of capabilities, they are able to extrapolate this into drug discovery. Ross believes that Biosortia’s ability to mine microbiome on such a large scale will change drug discovery in the coming years.

   Apple Podcasts

   Google Podcasts

   Spotify Podcasts

Summary – Delighted to share Episode 1, Season 1 of The Sophia Consulting Firm’s “Amplifying Scientific Innovation Podcast” with Ross Youngs, Founder and CEO, of Biosortia Pharmaceuticals.

Summary – Ross Youngs has spent over 30 years inventing products, technologies and processes for a variety of industries, and holds over 75 patents worldwide. He is driven to innovate by a focus on what is better, faster and less expensive. Ross’ recent major innovations include an R&D 100 Award for collaboration on biopolymer technologies. In 2009, Biosortia was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology, which helped lead to the development of Biosortia’s drug discovery platform.